Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Recombinant and Autologous Platelet Derived Growth Factors for Wound Healing and Other Non Orthopedic Conditions is addressed separately in medical policy 00262.

Note: Bioengineered Skin and Soft Tissue Substitutes is addressed separately in medical policy 00572.

Note: Orthopedic Applications of Stem Cell Therapy (Including Allograft and Bone Substitute Products Used With Autologous Bone Marrow) is addressed separately in medical policy 00258.

When Services Are Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider treatment of nonhealing and not clinically infected diabetic foot ulcers using the following human amniotic membrane (HAM) products (Affinity®, AmnioBand® Membrane, Biovance®, EpiCord®, Epifix®, Grafix™)‡ to be eligible for coverage** when the following criteria are met:

- Initial treatment may be approved for up to 4 applications over 6 weeks period per nonhealing wound that is not infected and patient agrees to comply with adequate mechanical offloading (see Policy Guidelines); or
- Additional applications after initial 6 weeks may be eligible for coverage when following criteria are met:
  - Documented objective evidence of wound healing (e.g. development and presence of healthy granulation tissue with progressive wound contracture or decreasing depth); and
Amniotic Membrane and Amniotic Fluid

Policy #  00458
Original Effective Date:  08/19/2015
Current Effective Date:  06/12/2023

- Approved HAM product is applied no more frequently than in one-week intervals; and
- Patient remains compliant with adequate mechanical offloading; and
- Continued treatment may be approved for up to 4 additional applications over 6 more weeks, per wound treated.

Based on review of available data, the Company may consider HAM grafts with or without suture or glue (e.g., Prokera®, AmbioDisk™, AmnioGraft®, Artacent Ocular, Vendaje Optic™)† for the treatment of any of the following ophthalmic indications to be eligible for coverage:‡

- Neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy; or
- Corneal ulcers and melts that do not respond to initial conservative therapy; or
- Corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment; or
- Corneal perforation when corneal tissue is not immediately available; or
- Bullous keratopathy as a palliative measure in individuals who are not candidates for curative treatment (eg, endothelial or penetrating keratoplasty); or
- Partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient; or
- Moderate or severe Stevens-Johnson syndrome; or
- Persistent epithelial defects that do not respond to conservative therapy; or
- Severe dry eye (DEWS 3 or 4) with ocular surface damage and inflammation that remains symptomatic after Steps 1, 2, and 3 of the dry eye disease management algorithm (see Policy Guidelines); or
- Pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft (e.g. extensive, double, or recurrent pterygium); or
- Moderate or severe acute ocular chemical burn.

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

Based on review of available data, the Company considers injection of micronized or particulated human amniotic membrane for all indications, including but not limited to treatment of osteoarthritis and plantar fasciitis, to be investigational.*

Based on review of available data, the Company considers human amniotic membrane grafts with or without suture for all ophthalmic indications not outlined above to be investigational.*

Based on review of available data, the Company considers injection of human amniotic fluid for all indications to be investigational.*

Based on review of available data, the Company considers all other human amniotic products (eg, derived from amnion, chorion, amniotic fluid, umbilical cord, or Wharton’s jelly) not listed above to be investigational.*

Based on review of available data, the Company considers use for all other indications not listed above to be investigational* including but not limited to:

- Treatment of lower-extremity ulcers due to venous insufficiency
- Repair following Mohs micrographic surgery
- When criteria above are not met including using more than 8 applications beyond 12 weeks for diabetic foot ulcers

Policy Guidelines
Non-healing of diabetic wounds is defined as less than a 20% decrease in wound area with standard wound care for at least 2 weeks, based on the entry criteria for clinical trials (eg, Zelen et al [2015]). Tables PG1 and PG2 list the medically necessary and investigational amniotic products that have an HCPCS code.

Table PG1 Amniotic Products Listed in the Policy Statements

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Supplier</th>
<th>HCPCS Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Affinity®‡</td>
<td>Organogenesis (previously NuTech Medical)</td>
<td>Q4159</td>
</tr>
</tbody>
</table>

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Supplier</th>
<th>HCPCS Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>AmnioBand®‡ Membrane</td>
<td>MTF Wound Care</td>
<td>Q4151</td>
</tr>
<tr>
<td>Biovance®‡</td>
<td>Celularity</td>
<td>Q4154</td>
</tr>
<tr>
<td>Epifix®‡</td>
<td>MiMedx</td>
<td>Q4186</td>
</tr>
<tr>
<td>Epicord®‡</td>
<td>MiMedx</td>
<td>Q4187</td>
</tr>
<tr>
<td>Grafix®‡</td>
<td>Osiris</td>
<td>Q4132, Q4133</td>
</tr>
</tbody>
</table>

Table PG2 Other Amniotic Products with HCPCS Codes

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Supplier</th>
<th>HCPCS Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allogen</td>
<td>Vivex Biomedical</td>
<td>Q4212</td>
</tr>
<tr>
<td>AlloWrap™‡</td>
<td>AlloSource</td>
<td>Q4150</td>
</tr>
<tr>
<td>AmnioAMP-MP</td>
<td>Stratus BioSystems</td>
<td>Q4250</td>
</tr>
<tr>
<td>Amnioarmor™‡</td>
<td>Tissue Transplant Technology</td>
<td>Q4188</td>
</tr>
<tr>
<td>AmnioBand®‡ Particulate</td>
<td>MTF Wound Care</td>
<td>Q4168</td>
</tr>
<tr>
<td>AmnioExcel®‡</td>
<td>Derma Sciences</td>
<td>Q4137</td>
</tr>
<tr>
<td>Amnio-maxx or Manio-maxx lite</td>
<td>Royal Biologics</td>
<td>Q4239</td>
</tr>
<tr>
<td>Amniotext</td>
<td>Regenerative Labs</td>
<td>Q4245</td>
</tr>
<tr>
<td>Amniowound</td>
<td>Alpha Tissue</td>
<td>Q4181</td>
</tr>
<tr>
<td>Amnion bio or Axomembrane</td>
<td>Axolotl Biologix</td>
<td>Q4211</td>
</tr>
<tr>
<td>Amniocore™†</td>
<td>Stability Biologics</td>
<td>Q4227</td>
</tr>
<tr>
<td>Amniocyte</td>
<td>Predictive Biotech</td>
<td>Q4242</td>
</tr>
<tr>
<td>AmnioMatrix®‡</td>
<td>Integra Life Sciences</td>
<td>Q4139</td>
</tr>
<tr>
<td>Amniply</td>
<td>International Tissue</td>
<td>Q4249</td>
</tr>
</tbody>
</table>

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Amniotic Membrane and Amniotic Fluid

Policy #  00458  
Original Effective Date:  08/19/2015  
Current Effective Date:  06/12/2023

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Manufacturer</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amniorepair or Altiply</td>
<td>Zimmer Biomet</td>
<td>Q4235</td>
</tr>
<tr>
<td>Amniotext patch</td>
<td>Regenerative Labs</td>
<td>Q4247</td>
</tr>
<tr>
<td>AmnioWrap2™‡</td>
<td>Direct Biologics</td>
<td>Q4221</td>
</tr>
<tr>
<td>Articent ac (flowable)</td>
<td>Tides Medical</td>
<td>Q4189</td>
</tr>
<tr>
<td>Articent ac (patch)</td>
<td>Tides Medical</td>
<td>Q4190</td>
</tr>
<tr>
<td>Artacent®‡ Wound</td>
<td>Tides Medical</td>
<td>Q4169</td>
</tr>
<tr>
<td>Artacent®‡ Cord</td>
<td>Tides Medical</td>
<td>Q4126</td>
</tr>
<tr>
<td>Ascent</td>
<td>StimLabs</td>
<td>Q4213</td>
</tr>
<tr>
<td>Axolotl ambien or Axolotl Cryo</td>
<td>Axolotl Biology</td>
<td>Q4215</td>
</tr>
<tr>
<td>BioDDryFlex®‡</td>
<td>BioD</td>
<td>Q4138</td>
</tr>
<tr>
<td>BioDfence™‡</td>
<td>Integra Life Science</td>
<td>Q4140</td>
</tr>
<tr>
<td>BioNextPATCH</td>
<td>BioNext Solutions</td>
<td>Q4228</td>
</tr>
<tr>
<td>BioWound, BioWound Plus™‡, BioWound XPlus™‡</td>
<td>HRTª</td>
<td>Q4217</td>
</tr>
<tr>
<td>carePATCH</td>
<td>Extremity Care</td>
<td>Q4236</td>
</tr>
<tr>
<td>Cellesta/Cellesta duo</td>
<td>Ventris Medical</td>
<td>Q4184</td>
</tr>
<tr>
<td>Cellesta Cord</td>
<td>Ventris Medical</td>
<td>Q4214</td>
</tr>
<tr>
<td>Cellesta flowable</td>
<td>Ventris Medical</td>
<td>Q4185</td>
</tr>
<tr>
<td>Clarix®‡</td>
<td>Amniox Medical</td>
<td>Q4156</td>
</tr>
<tr>
<td>Clarix®‡ Flo</td>
<td>Amniox Medical</td>
<td>Q4155</td>
</tr>
<tr>
<td>Cogenex flowable amnion</td>
<td>Ventris Medical</td>
<td>Q4230</td>
</tr>
<tr>
<td>Cogenex amniotic membrane</td>
<td>Ventris Medical</td>
<td>Q4229</td>
</tr>
<tr>
<td>Corecyte</td>
<td>Predictive Biotech</td>
<td>Q4240</td>
</tr>
</tbody>
</table>

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Amniotic Membrane and Amniotic Fluid

Policy #  00458  
Original Effective Date:  08/19/2015  
Current Effective Date:  06/12/2023

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Manufacturer</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corplex</td>
<td>StimLabs</td>
<td>Q4232</td>
</tr>
<tr>
<td>Corplex P</td>
<td>StimLabs</td>
<td>Q4231</td>
</tr>
<tr>
<td>Coretext or Protext</td>
<td>Regenerative Labs</td>
<td>Q4246</td>
</tr>
<tr>
<td>Cryo-cord</td>
<td>Royal Biologics</td>
<td>Q4237</td>
</tr>
<tr>
<td>Cygnus</td>
<td>Vivex Biomedical</td>
<td>Q4170</td>
</tr>
<tr>
<td>Dermacyte</td>
<td>Merakris Therapeutics</td>
<td>Q4248</td>
</tr>
<tr>
<td>Dermavest™ or Plurivest</td>
<td>AediCell®</td>
<td>Q4153</td>
</tr>
<tr>
<td>Derm-maxx</td>
<td>Royal Biologics</td>
<td>Q4238</td>
</tr>
<tr>
<td>Epifix Injectable</td>
<td>MiMedx</td>
<td>Q4145</td>
</tr>
<tr>
<td>Floweramnioflo</td>
<td>Flower Orthopedics</td>
<td>Q4177</td>
</tr>
<tr>
<td>Floweramniopatch</td>
<td>Flower Orthopedics</td>
<td>Q4178</td>
</tr>
<tr>
<td>Fluid flow or Fluid GF</td>
<td>BioLab Sciences</td>
<td>Q4206</td>
</tr>
<tr>
<td>Genesis</td>
<td>Genesis Biologics</td>
<td>Q4198</td>
</tr>
<tr>
<td>Guardian/AmnioBand®</td>
<td>MTF Wound Care</td>
<td>Q4151</td>
</tr>
<tr>
<td>Interfyl®</td>
<td>Celularity</td>
<td>Q4171</td>
</tr>
<tr>
<td>Matrion</td>
<td>LifeNet Health</td>
<td>Q4201</td>
</tr>
<tr>
<td>Neopatch or Therion</td>
<td>CryoLife</td>
<td>Q4176</td>
</tr>
<tr>
<td>Neox® Cord</td>
<td>Amniox Medical</td>
<td>Q4148</td>
</tr>
<tr>
<td>Neox® Flo</td>
<td>Amniox Medical</td>
<td>Q4155</td>
</tr>
<tr>
<td>Neox® Wound</td>
<td>Amniox Medical</td>
<td>Q4156</td>
</tr>
<tr>
<td>Novachor</td>
<td>Organogenisis</td>
<td>Q4191</td>
</tr>
<tr>
<td>Novafix®</td>
<td>Triad Life Sciences</td>
<td>Q4208</td>
</tr>
</tbody>
</table>
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Manufacturer</th>
<th>Provider Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novafix DL</td>
<td>Triad Life Sciences</td>
<td>Q4254</td>
</tr>
<tr>
<td>NuShield</td>
<td>Organogenesis</td>
<td>Q4160</td>
</tr>
<tr>
<td>PalinGen®† Membrane</td>
<td>Amnio ReGen Solutions</td>
<td>Q4173</td>
</tr>
<tr>
<td>PalinGen®† SportFlow</td>
<td>Amnio ReGen Solutions</td>
<td>Q4174</td>
</tr>
<tr>
<td>Plurivest™‡</td>
<td>AediCell</td>
<td>Q4153</td>
</tr>
<tr>
<td>Polycyte</td>
<td>Predictive Biotech</td>
<td>Q4241</td>
</tr>
<tr>
<td>Procenta</td>
<td>Lucina BioSciences</td>
<td>Q4244</td>
</tr>
<tr>
<td>Reguard</td>
<td>New Life Medical</td>
<td>Q4255</td>
</tr>
<tr>
<td>Restorigin</td>
<td>UMTB Biomedical</td>
<td>Q4191</td>
</tr>
<tr>
<td>Restorigin Injectable</td>
<td>UMTB Biomedical</td>
<td>Q4192</td>
</tr>
<tr>
<td>Revita</td>
<td>StimLabs</td>
<td>Q4180</td>
</tr>
<tr>
<td>Revitalon™‡</td>
<td>Medline Industries</td>
<td>Q4157</td>
</tr>
<tr>
<td>Surgenex, Surfactor, and Nudyn</td>
<td>Surgenex</td>
<td>Q4233</td>
</tr>
<tr>
<td>Surgicord</td>
<td>Synergy Biologics</td>
<td>Q4218</td>
</tr>
<tr>
<td>SurgiGRAFT™‡</td>
<td>Synergy Biologics</td>
<td>Q4183</td>
</tr>
<tr>
<td>WoundEx®‡</td>
<td>Skye Biologics</td>
<td>Q4163</td>
</tr>
<tr>
<td>WoundEx®‡ Flow</td>
<td>Skye Biologics</td>
<td>Q4162</td>
</tr>
<tr>
<td>Woundfix, Woundfix Plus, Wounfix XPlus (see BioWound above)</td>
<td>HRT</td>
<td>Q4217</td>
</tr>
<tr>
<td>Xcellerate</td>
<td>Precise Bioscience</td>
<td>Q4234</td>
</tr>
<tr>
<td>Xwrap</td>
<td>Applied Biologics</td>
<td>Q4204</td>
</tr>
</tbody>
</table>

HRT: Human Regenerative Technologies; MTF: Musculoskeletal Transplant Foundation

*Processed by HRT and marketed under different tradename

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

Tear Film and Ocular Surface Society staged management for dry eye disease (Jones et al, 2017)

Step 1:
- Education regarding the condition, its management, treatment and prognosis
- Modification of local environment
- Education regarding potential dietary modifications (including oral essential fatty acid supplementation)
- Identification and potential modification/elimination of offending systemic and topical medications
- Ocular lubricants of various types (if meibomian gland dysfunction is present, then consider lipid containing supplements)
- Lid hygiene and warm compresses of various types

Step 2:
If above options are inadequate consider:
- Non-preserved ocular lubricants to minimize preservative-induced toxicity
- Tea tree oil treatment for Demodex (if present)
- Tear conservation
- Punctal occlusion
- Moisture chamber spectacles/goggles
- Overnight treatments (such as ointment or moisture chamber devices)
- In-office, physical heating and expression of the meibomian glands
- In-office intense pulsed light therapy for meibomian gland dysfunction
- Prescription drugs to manage dry eye disease
- Topical antibiotic or antibiotic/steroid combination applied to the lid margins for anterior blepharitis (if present)
- Topical corticosteroid (limited-duration)
- Topical secretagogues
- Topical non-glucocorticoid immunomodulatory drugs (such as cyclosporine)
- Topical LFA-1 antagonist drugs (such as lifitegrast)
- Oral macrolide or tetracycline antibiotics

Step 3:
If above options are inadequate consider:
- Oral secretagogues
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

- Autologous/allogeneic serum eye drops
- Therapeutic contact lens options
- Soft bandage lenses
- Rigid scleral lenses

Step 4:
If above options are inadequate consider:
- Topical corticosteroid for longer duration
- Amniotic membrane grafts
- Surgical punctal occlusion
- Other surgical approaches (eg tarsorrhaphy, salivary gland transplantation)

**Dry eye severity level DEWS 3 to 4**
Discomfort, severity, and frequency - Severe frequent or constant
Visual symptoms - chronic and/or constant, limiting to disabling
Conjunctival Injection - +/- or +/+
Conjunctive Staining - moderate to marked
Corneal Staining - marked central or severe punctate erosions
Corneal/tear signs - Filamentary keratitis, mucus clumping, increase in tear debris
Lid/meibomian glands - Frequent
Tear film breakup time - < 5
Schirmer score (mm/5 min) - < 5

**Background/Overview**
**Human Amniotic Membrane**
Human amniotic membrane (HAM) consists of 2 conjoined layers, the amnion, and chorion, and forms the innermost lining of the amniotic sac or placenta. When prepared for use as an allograft, the membrane is harvested immediately after birth, cleaned, sterilized, and either cryopreserved or dehydrated. Many products available using amnion, chorion, amniotic fluid, and umbilical cord are being studied for the treatment of a variety of conditions, including chronic full-thickness diabetic lower-extremity ulcers, venous ulcers, knee osteoarthritis, plantar fasciitis, and ophthalmic conditions. The products are formulated either as patches, which can be applied as wound covers, or
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

as suspensions or particulates, or connective tissue extractions, which can be injected or applied topically.

Fresh amniotic membrane contains collagen, fibronectin, and hyaluronic acid, along with a combination of growth factors, cytokines, and anti-inflammatory proteins such as interleukin-1 receptor antagonist. There is evidence that the tissue has anti-inflammatory, antifibroblastic, and antimicrobial properties. HAM is considered nonimmunogenic and has not been observed to cause a substantial immune response. It is believed that these properties are retained in cryopreserved HAM and HAM products, resulting in a readily available tissue with regenerative potential. In support, 1 HAM product has been shown to elute growth factors into saline and stimulate the migration of mesenchymal stem cells, both in vitro and in vivo.

Use of a HAM graft, which is fixated by sutures, is an established treatment for disorders of the corneal surface, including neurotrophic keratitis, corneal ulcers and melts, following pterygium repair, Stevens-Johnson syndrome, and persistent epithelial defects. Amniotic membrane products that are inserted like a contact lens have more recently been investigated for the treatment of corneal and ocular surface disorders. Amniotic membrane patches are also being evaluated for the treatment of various other conditions, including skin wounds, burns, leg ulcers, and prevention of tissue adhesion in surgical procedures. Additional indications studied in preclinical models include tendonitis, tendon repair, and nerve repair. The availability of HAM opens the possibility of regenerative medicine for an array of conditions.

Amniotic Fluid

Amniotic fluid surrounds the fetus during pregnancy and provides protection and nourishment. In the second half of gestation, most of the fluid is a result of micturition and secretion from the respiratory tract and gastrointestinal tract of the fetus, along with urea. The fluid contains proteins, carbohydrates, peptides, fats, amino acids, enzymes, hormones, pigments, and fetal cells. Use of human and bovine amniotic fluid for orthopedic conditions was first reported in 1927. Amniotic fluid has been compared with synovial fluid, containing hyaluronan, lubricant, cholesterol, and cytokines. Injection of amniotic fluid or amniotic fluid-derived cells is currently being evaluated for the treatment of osteoarthritis and plantar fasciitis.

Amniotic membrane and amniotic fluid are also being investigated as sources of pluripotent stem cells. Pluripotent stem cells can be cultured and are capable of differentiation toward any cell type.
Amniotic Membrane and Amniotic Fluid

Policy # 00458  
Original Effective Date: 08/19/2015  
Current Effective Date: 06/12/2023

**FDA or Other Governmental Regulatory Approval**  
**U.S. Food and Drug Administration (FDA)**

The U.S. FDA regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, Title 21, parts 1270 and 1271. In 2017, the FDA published clarification of what is considered minimal manipulation and homologous use for human cells, tissues, and cellular and tissue-based products (HCT/Ps).

HCT/Ps are defined as human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient. If an HCT/P does not meet the criteria below and does not qualify for any of the stated exceptions, the HCT/P will be regulated as a drug, device, and/or biological product and applicable regulations and premarket review will be required.

An HCT/P is regulated solely under section 361 of the PHS Act and 21 CFR Part 1271 if it meets all of the following criteria:

1. "The HCT/P is minimally manipulated;"
2. The HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent;
3. The manufacture of the HCT/P does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT/P; and
4. Either:
   i. The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function; or
   ii. The HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, and:
      a. Is for autologous use;
      b. Is for allogeneic use in a first-degree or second-degree blood relative; or
      c. Is for reproductive use."

The guidance provides the following specific examples of homologous and non-homologous use for amniotic membrane:
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

a. "Amniotic membrane is used for bone tissue replacement to support bone regeneration following surgery to repair or replace bone defects. This is not a homologous use because bone regeneration is not a basic function of amniotic membrane.
b. An amniotic membrane product is used for wound healing and/or to reduce scarring and inflammation. This is not homologous use because wound healing and reduction of scarring and inflammation are not basic functions of amniotic membrane.
c. An amniotic membrane product is applied to the surface of the eye to cover or offer protection from the surrounding environment in ocular repair and reconstruction procedures. This is homologous use because serving as a covering and offering protection from the surrounding environment are basic functions of amniotic membrane."

The FDA noted the intention to exercise enforcement discretion for the next 36 months after publication of the guidance.

In 2003, Prokera was cleared for marketing by the FDA through the 510(k) process for the ophthalmic conformer that incorporates amniotic membrane (K032104). The FDA determined that this device was substantially equivalent to the Symblepharon Ring. The Prokera device is intended “for use in eyes in which the ocular surface cells have been damaged, or underlying stroma is inflamed and scarred.” The development of Prokera, a commercially available product, was supported in part by the National Institute of Health and the National Eye Institute.

AmnioClip (FORTECH GmbH) is a ring designed to hold the amniotic membrane in the eye without sutures or glue fixation. A mounting device is used to secure the amniotic membrane within the AmnioClip. The AmnioClip currently has CE approval in Europe.

**Rationale/Source**
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

Several commercially available forms of HAM and amniotic fluid can be administered by patches, topical application, or injection. Amniotic membrane and amniotic fluid are being evaluated for the treatment of a variety of conditions, including chronic full-thickness diabetic lower-extremity ulcers, venous ulcers, knee osteoarthritis, plantar fasciitis, and ophthalmic conditions.

Summary of Evidence
Diabetic Lower-Extremity Ulcers
For individuals who have non-healing diabetic lower-extremity ulcers who receive a patch or flowable formulation of HAM or placental membrane (ie, Affinity, AmnioBand Membrane, AmnioExcel, Biovance, EpiCord, EpiFix, Grafix), the evidence includes randomized controlled trials (RCTs). Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. The RCTs evaluating amniotic and placental membrane products for the treatment of non-healing (<20% healing with ≥2 weeks of standard care) diabetic lower-extremity ulcers have compared HAM with standard care or with an established advanced wound care product. These trials used wound closure as the primary outcome measure, and some used power analysis, blinded assessment of wound healing, and intention-to-treat analysis. For the HAM products that have been sufficiently evaluated (ie, Affinity, AmnioBand Membrane, Biovance, EpiCord, EpiFix, Grafix), results have shown improved outcomes compared with standard care, and outcomes that are at least as good as an established advanced wound care product. Improved health outcomes in the RCTs are supported by multicenter registries. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Lower-Extremity Ulcers due to Venous Insufficiency
For individuals who have lower-extremity ulcers due to venous insufficiency who receive a patch or flowable formulation of HAM, the evidence includes 2 RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. The published evidence on HAM for the treatment of venous leg ulcers includes 2 multicenter RCTs with EpiFix. One RCT reported a larger percent wound closure at 4 weeks, but the percentage of individuals with complete wound closure at 4 weeks did not differ between EpiFix and the standard of care. A second RCT evaluated complete wound closure at 12 weeks after weekly application of EpiFix or standard dressings with compression, but interpretation is limited by methodologic concerns. Two additional studies with other HAM products have been completed but not published, raising further questions about the efficacy of HAM for venous insufficiency ulcers. Therefore, corroboration with well-designed and well-conducted RCTs evaluating wound healing is needed to demonstrate efficacy for this
Amniotic Membrane and Amniotic Fluid

Policy #   00458
Original Effective Date:   08/19/2015
Current Effective Date:   06/12/2023

indication. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Osteoarthritis
For individuals who have knee osteoarthritis who receive an injection of suspension or particulate formulation of HAM or amniotic fluid, the evidence includes a feasibility study. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The pilot study assessed the feasibility of a larger RCT evaluating HAM injection. Additional trials, which will have a larger sample size and longer follow-up, are needed to permit conclusions on the effect of this treatment. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Plantar Fasciitis
The evidence on injection of amniotic membrane for the treatment of plantar fasciitis includes preliminary studies and a larger (N =145) patient-blinded comparison of micronized injectable-HAM and placebo control. Injection of micronized amniotic membrane resulted in greater improvements in the visual analog score for pain and the Foot Functional Index compared to placebo controls. The primary limitation of the study is that this is an interim report with 12-month results pending. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Ophthalmic Conditions
Sutured HAM transplant has been used for many years for the treatment of ophthalmic conditions. Many of these conditions are rare, leading to difficulty in conducting RCTs. The rarity, severity, and variability of the ophthalmic condition was taken into consideration in evaluating the evidence.

Neurotrophic Keratitis with Ocular Surface Damage and Inflammation That Does Not Respond to Conservative Therapy
For individuals who have neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy who receive HAM, the evidence includes an RCT. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. An RCT of 30 individuals showed no benefit of sutured HAM graft compared to tarsorrhaphy or bandage contact lens. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

Corneal Ulcers and Melts That Do Not Respond to Initial Medical Therapy
For individuals who have corneal ulcers and melts, that do not respond to initial medical therapy who receive HAM, the evidence includes a systematic review of primarily case series and a non-randomized comparative study. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. Corneal ulcers and melts are uncommon and variable and additional RCTs are not expected. The systematic review showed healing in 97% of individuals with an improvement of vision in 53% of eyes. One retrospective comparative study with 22 individuals found more rapid and complete epithelialization and more individuals with a clinically significant improvement in visual acuity following early treatment with self-retained amniotic membrane when compared to historical controls. Corneal ulcers and melts are uncommon and variable and RCTs are not expected. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Corneal Perforation When There is Active Inflammation After Corneal Transplant Requiring Adjunctive Treatment
For individuals who have corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment who receive HAM, the evidence is limited. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. No comparative evidence was identified for this indication. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Bullous Keratopathy as a Palliative Measure in Individuals Who are Not Candidates for a Curative Treatment (eg, Endothelial or Penetrating Keratoplasty)
For individuals who have bullous keratopathy and who are not candidates for curative treatment (eg, endothelial or penetrating keratoplasty) who receive HAM, the evidence includes a RCT. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. An RCT found no advantage of sutured HAM over the simpler stromal puncture procedure for the treatment of pain from bullous keratopathy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Partial Limbal Stem Cell Deficiency with Extensive Diseased Tissue Where Selective Removal Alone is Not Sufficient
For individuals who have partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient who receive HAM, the evidence is limited. Relevant
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

Outcomes are symptoms, morbid events, functional outcomes, and quality of life. No comparative trials were identified on HAM for limbal stem cell deficiency. Improvement in visual acuity has been reported for some individuals who have received HAM in conjunction with removal of the diseased limbus. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Moderate or Severe Stevens-Johnson Syndrome
For individuals who have moderate or severe Stevens-Johnson syndrome who receive HAM, the evidence includes a RCT. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. The evidence on HAM for the treatment of Stevens-Johnson syndrome (includes 1 RCT with 25 individuals [50 eyes]) found improved symptoms and function with HAM compared to medical therapy alone. Large RCTs are unlikely due to the severity and rarity of the disease. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Persistent Epithelial Defects and Ulceration That Do Not Respond to Conservative Therapy
For individuals who have persistent epithelial defects that do not respond to conservative therapy who receive HAM, the evidence is limited. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. No comparative trials were identified on persistent epithelial defects and ulceration. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Severe Dry Eye with Ocular Surface Damage and Inflammation That Does Not Respond to Conservative Therapy
For individuals who have severe dry eye with ocular surface damage and inflammation that does not respond to conservative therapy, who receive HAM, the evidence includes an RCT and a large case series. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. The evidence on HAM for severe dry eye with ocular surface damage and inflammation includes an RCT with 20 individuals and a retrospective series of 84 individuals (97 eyes). Placement of self-retained HAM for 2 to 11 days reduced symptoms and restored a smooth corneal surface and corneal nerve density for as long as 3 months. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

Moderate or Severe Acute Ocular Chemical Burns
For individuals who have moderate or severe acute ocular chemical burn who receive HAM, the evidence includes 3 RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. Evidence includes a total of 197 individuals with acute ocular chemical burns who were treated with HAM transplantation plus medical therapy or medical therapy alone. Two of the 3 RCTs did not show a faster rate of epithelial healing, and there was no significant benefit for other outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Corneal Perforation When Corneal Tissue is Not Immediately Available
For individuals who have corneal perforation when corneal tissue is not immediately available who receive sutured HAM, the evidence is limited. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. The standard treatment for corneal perforation is corneal transplantation, however, HAM may provide temporary coverage of the severe defect when corneal tissue is not immediately available. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Pterygium Repair When There is Insufficient Healthy Tissue to Create a Conjunctival Autograft
For individuals who have pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft who receive HAM, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. Systematic reviews of RCTs have been published that found that conjunctival or limbal autograft is more effective than HAM graft in reducing the rate of pterygium recurrence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Repair Following Mohs Micrographic Surgery
For individuals who have undergone Mohs micrographic surgery for skin cancer on the face, head, neck, or dorsal hand who receive human amniotic/chorionic membrane, the evidence includes a nonrandomized, comparative study and no RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. A retrospective analysis using data from medical records compared a dehydrated human amniotic/chorionic membrane product (dHACM, Epifix) to repair using autologous surgery in 143 propensity-score matched pairs of individuals requiring same-day reconstruction after Mohs microsurgery for skin cancer on the head, face, or neck. A greater
Amniotic Membrane and Amniotic Fluid

Policy #  00458
Original Effective Date:  08/19/2015
Current Effective Date:  06/12/2023

The proportion of individuals who received dHACM repair experienced zero complications (97.9% vs. 71.3%; p<.0001; relative risk 13.97; 95% CI, 4.33 to 43.12). Placental allograft reconstructions developed less infection (p=.004) and were less likely to experience poor scar cosmesis (p<.0001). This study is limited by its retrospective observational design. Well-designed and conducted prospective studies are lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Additional Information

2019 Input

Clinical input was sought to help determine whether the use of human amniotic membrane graft either without or with suture fixation for several ophthalmic conditions would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 2 respondents, including 1 specialty society-level response and 1 physician-level response identified through specialty societies including physicians with academic medical center affiliations.

Clinical input supported the use of amniotic membrane in individuals with the following indications:

- Neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy. Non-sutured HAM in an office setting would be preferred to avoid a delay in treatment associated with scheduling a surgical treatment.
- Corneal ulcers and melts that do not respond to initial medical therapy. Non-sutured HAM in an office setting would be preferred to avoid a delay in treatment associated with scheduling a surgical treatment.
- Corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment.
- Bullous keratopathy and who are not candidates for curative treatment (eg, endothelial or penetrating keratoplasty) as an alternative to stromal puncture.
- Partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient.
- Persistent epithelial defects and ulcerations that do not respond to conservative therapy.
- Severe dry eye with ocular surface damage and inflammation that does not respond to conservative therapy.
- Moderate or severe acute ocular chemical burn.
- Corneal perforation when corneal tissue is not immediately available.
Amniotic Membrane and Amniotic Fluid

Policy #  00458
Original Effective Date:  08/19/2015
Current Effective Date:  06/12/2023

- Pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft.

Supplemental Information
Clinical Input from Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2019 Input
Clinical input was sought to help determine whether the use of human amniotic membrane graft either without or with suture fixation for several ophthalmic conditions would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 2 respondents, including 1 specialty society-level response and 1 physician-level response identified through specialty societies including physicians with academic medical center affiliations.

Clinical input supported the use of amniotic membrane in individuals with the following indications:
- Neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy. Non-sutured HAM in an office setting would be preferred to avoid a delay in treatment associated with scheduling a surgical treatment.
- Corneal ulcers and melts that do not respond to initial medical therapy. Non-sutured HAM in an office setting would be preferred to avoid a delay in treatment associated with scheduling a surgical treatment.
- Corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment.
- Bullous keratopathy and who are not candidates for curative treatment (eg, endothelial or penetrating keratoplasty) as an alternative to stromal puncture.
- Partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient.
- Persistent epithelial defects and ulcerations that do not respond to conservative therapy.
- Severe dry eye with ocular surface damage and inflammation that does not respond to conservative therapy.
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

- Moderate or severe acute ocular chemical burn.
- Corneal perforation when corneal tissue is not immediately available.
- Pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

Society for Vascular Surgery et al.
In 2016, the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine made the following recommendation: “For DFUs [diabetic foot ulcers] that fail to demonstrate improvement (>50% wound area reduction) after a minimum of 4 weeks of standard wound therapy, we recommend adjunctive wound therapy options. These include negative pressure therapy, biologics (platelet-derived growth factor [PDGF], living cellular therapy, extracellular matrix products, amnionic membrane products), and hyperbaric oxygen therapy. Choice of adjuvant therapy is based on clinical findings, availability of therapy, and cost-effectiveness; there is no recommendation on ordering of therapy choice.”

Tear Film and Ocular Surface Society
In 2017, the Tear Film and Ocular Surface Society published the Dry Eye Workshop II (DEWS) management and therapy report. The report evaluated the evidence on treatments for dry eye and provided the following treatment algorithm for dry eye disease management:

Step 1:
- Education regarding the condition, its management, treatment, and prognosis
- Modification of local environment
- Education regarding potential dietary modifications (including oral essential fatty acid supplementation)
- Identification and potential modification/elimination of offending systemic and topical medications
Amniotic Membrane and Amniotic Fluid

Policy #  00458
Original Effective Date:  08/19/2015
Current Effective Date:  06/12/2023

- Ocular lubricants of various types (if meibomian gland dysfunction is present, then consider lipid containing supplements)
- Lid hygiene and warm compresses of various types

Step 2:
If above options are inadequate consider:
- Non-preserved ocular lubricants to minimize preservative-induced toxicity
- Tea tree oil treatment for Demodex (if present)
- Tear conservation
- Punctal occlusion
- Moisture chamber spectacles/goggles
- Overnight treatments (such as ointment or moisture chamber devices)
- In-office, physical heating and expression of the meibomian glands
- In-office intense pulsed light therapy for meibomian gland dysfunction
- Prescription drugs to manage dry eye disease
- Topical antibiotic or antibiotic/steroid combination applied to the lid margins for anterior blepharitis (if present)
- Topical corticosteroid (limited-duration)
- Topical secretagogues
- Topical non-glucocorticoid immunomodulatory drugs (such as cyclosporine)
- Topical LFA-1 antagonist drugs (such as lifitegrast)
- Oral macrolide or tetracycline antibiotics

Step 3:
If above options are inadequate consider:
- Oral secretagogues
- Autologous/allogeneic serum eye drops
- Therapeutic contact lens options
- Soft bandage lenses
- Rigid scleral lenses

Step 4:
If above options are inadequate consider:
- Topical corticosteroid for longer duration
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

- Amniotic membrane grafts
- Surgical punctal occlusion
- Other surgical approaches (e.g., tarsorrhaphy, salivary gland transplantation)

Wound Healing Society
In 2016, the Wound Healing Society updated their guidelines on diabetic foot ulcer treatment. The Society concluded that there was level 1 evidence that cellular and acellular skin equivalents improve diabetic foot ulcer healing, noting that, “healthy living skin cells assist in healing DFUs [diabetic foot ulcers] by releasing therapeutic amounts of growth factors, cytokines, and other proteins that stimulate the wound bed.” References from 2 randomized controlled trials on amniotic membrane were included with references on living and acellular bioengineered skin substitutes.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04457752</td>
<td>A Randomized Controlled Multicentre Clinical Trial, Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)‡ and Standard of Care Versus Standard of Care Alone in the Healing of Chronic Diabetic Foot Ulcers</td>
<td>124</td>
<td>Mar 2023</td>
</tr>
</tbody>
</table>
## Amniotic Membrane and Amniotic Fluid

Policy # 00458  
Original Effective Date: 08/19/2015  
Current Effective Date: 06/12/2023

<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Study Title</th>
<th>Number</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03390920</td>
<td>Evaluation of Outcomes With Amniotic Fluid for Musculoskeletal Conditions</td>
<td>200</td>
<td>Jan 2030</td>
</tr>
<tr>
<td>NCT04612023</td>
<td>A Prospective, Double-Blinded, Randomized Controlled Trial of an Amniotic Membrane Allograft Injection Comparing Two Doses (1 mL and 2 mL Injection) and a Placebo (Sterile Saline) in the Treatment of Osteoarthritis of the Knee</td>
<td>90</td>
<td>Jul 2022</td>
</tr>
<tr>
<td>NCT04553432</td>
<td>Dry Eye OmniLenz Application of Omnigen Research Study</td>
<td>130</td>
<td>Jul 2024</td>
</tr>
<tr>
<td>NCT04599673</td>
<td>Prospective Analysis of Intraoperative AMNIOGEN®† Injection in Individuals With Rotator Cuff Tear</td>
<td>100</td>
<td>Sep 2022</td>
</tr>
<tr>
<td>NCT04636229</td>
<td>A Phase 3 Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of Amniotic Suspension Allograft (ASA) in Individuals With Osteoarthritis of the Knee</td>
<td>474</td>
<td>Dec 2023</td>
</tr>
<tr>
<td>NCT03855514</td>
<td>A Prospective, Multicenter, Randomized, Controlled Clinical Study Of NuShield®† and Standard of Care (SOC) Compared to SOC Alone For The Management Of Diabetic Foot Ulcers</td>
<td>200</td>
<td>Dec 2021 (Recruiting)</td>
</tr>
</tbody>
</table>

**Unpublished**

<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Study Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03855514</td>
<td>A Prospective, Multicenter, Randomized, Controlled Clinical Study Of NuShield®† and Standard of Care (SOC) Compared to SOC Alone For The Management Of Diabetic Foot Ulcers</td>
</tr>
</tbody>
</table>

NCT: national study  
clinical trial.  

---

**References**

Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023


©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023


Policy History
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023
08/06/2015 Medical Policy Committee review
08/19/2015 Medical Policy Implementation Committee approval. New policy.
08/04/2016 Medical Policy Committee review
08/17/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
08/03/2017 Medical Policy Committee review
08/23/2017 Medical Policy Implementation Committee approval. AmnioBand Membrane, Biovance, Epifix, Grafix considered medically necessary for diabetic foot ulcers; all other products and indications are investigational. Sutured amniotic membrane grafts

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
considered medically necessary for neurotrophic keratitis, corneal ulcers and melts, following pterygium repair, Stevens-Johnson syndrome, and persistent epithelial defects. Ophthalmic products added and discontinued product names removed from Table 1.

05/03/2018 Medical Policy Committee review
05/16/2018 Medical Policy Implementation Committee approval. Investigational indications clarified.
04/04/2019 Medical Policy Committee review
04/24/2019 Medical Policy Implementation Committee approval. EpiCord add to medically necessary statement for diabetic lower extremity ulcers. Sutured and non-sutured amniotic membrane may be considered medically necessary for specified ophthalmic conditions.

08/01/2019 Medical Policy Committee review
08/14/2019 Medical Policy Implementation Committee approval. Added criteria for non healing diabetic ulcers.
08/06/2020 Medical Policy Committee review
08/12/2020 Medical Policy Implementation Committee approval. 60-day provider notification required as proposed changes will result in more restrictive coverage criteria. Effective date is 11/01/2020.

Replaced “diabetic lower extremity ulcers” with “diabetic foot ulcers” in the eligible for coverage statement for treatment of nonhealing and not clinically infected diabetic foot ulcers. This change is proposed to make distinction/clarification between other lower extremity ulcers in diabetics and true non-healing diabetic foot ulcers.

Added the requirement that “patient agrees to comply with adequate mechanical offloading” for initial placement and similarly for continued treatment eligible for coverage criteria for additional applications, adding that “patient remains compliant with adequate mechanical offloading”.

Revised the Policy Guidelines definition of non-healing diabetic wounds was revised to “an ulcer that fails to demonstrate > 50% wound area reduction after a minimum of 4 weeks of standard wound therapy.” It replaces the previous definition that was worded as “fails to demonstrate 20% decrease in wound area with standard wound care for at least 2 weeks.”

08/05/2021 Medical Policy Committee review
08/11/2021 Medical Policy Implementation Committee approval. Brought back for clarification.
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

05/05/2022 Medical Policy Committee review
05/11/2022 Medical Policy Implementation Committee approval. AmnioGraft, Vendaje Optic and Artacent Ocular was added as eligible for coverage for HAM grafts with or without suture or glue. Added new investigational statement for repair following Mohs micrographic surgery.
05/04/2023 Medical Policy Committee review
05/10/2023 Medical Policy Implementation Committee approval. No change to coverage.
06/07/2023 Coding update
Next Scheduled Review Date: 05/2024

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.
Amniotic Membrane and Amniotic Fluid

Policy # 00458  
Original Effective Date: 08/19/2015  
Current Effective Date: 06/12/2023

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>15271, 15275, 17999, 65778, 65779, 65780</td>
</tr>
<tr>
<td>HCPCS</td>
<td>Q4100, Q4132, Q4133, Q4137, Q4138, Q4139, Q4140, Q4145, Q4148, Q4150, Q4151, Q4153, Q4154, Q4155, Q4156, Q4157, Q4159, Q4160, Q4162, Q4163, Q4168, Q4169, Q4170, Q4171, Q4173, Q4174, Q4176, Q4177, Q4178, Q4179, Q4181, Q4183, Q4184, Q4185, Q4186, Q4187, Q4188, Q4189, Q4190, Q4191, Q4192, Q4194, Q4198, Q4201, Q4204, Q4205, Q4206, Q4208, Q4209, Q4210, Q4211, Q4212, Q4213, Q4214, Q4215, Q4216, Q4217, Q4218, Q4219, Q4221, Q4227, Q4229, Q4230, Q4231, Q4232, Q4233, Q4234, Q4235, Q4237, Q4239, Q4240, Q4241, Q4242, Q4244, Q4245, Q4246, Q4247, Q4248, Q4249, Q4250, Q4251, Q4252, Q4253, Q4254, V2790</td>
</tr>
<tr>
<td>Add codes effective 1/1/2022: A2001, Q4199</td>
<td></td>
</tr>
<tr>
<td>Add codes effective 4/1/2022: Q4224, Q4225, Q4256, Q4257, Q4258</td>
<td></td>
</tr>
<tr>
<td>Add codes effective 7/1/2022: Q4259, Q4260, Q4261</td>
<td></td>
</tr>
<tr>
<td>Add code effective 12/01/2022: A4100</td>
<td></td>
</tr>
<tr>
<td>Add codes effective 01/01/2023: Q4236, Q4262, Q4263, Q4264</td>
<td></td>
</tr>
<tr>
<td>Add codes effective 04/01/2023: Q4265, Q4266, Q4267, Q4268, Q4269, Q4270, Q4271</td>
<td></td>
</tr>
<tr>
<td>Add codes effective 07/01/2023: Q4272, Q4273, Q4274, Q4275, Q4276, Q4277, Q4278, Q4280, Q4281, Q4282, Q4283, Q4284</td>
<td></td>
</tr>
</tbody>
</table>

ICD-10 Diagnosis

All related diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
Amniotic Membrane and Amniotic Fluid

Policy # 00458
Original Effective Date: 08/19/2015
Current Effective Date: 06/12/2023

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

   A. In accordance with nationally accepted standards of medical practice;
   B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
   C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company
Amniotic Membrane and Amniotic Fluid

Policy #  00458
Original Effective Date:  08/19/2015
Current Effective Date:  06/12/2023

recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.